These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30831650)

  • 1. [Pathological significance of NY-ESO-1 expression in the diagnosis of myxoid liposarcoma].
    Hei SM; Wei HJ; Chen H; Wang JG
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):225-230. PubMed ID: 30831650
    [No Abstract]   [Full Text] [Related]  

  • 2. NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms.
    Hemminger JA; Iwenofu OH
    Mod Pathol; 2013 Sep; 26(9):1204-10. PubMed ID: 23599152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas.
    Hemminger JA; Ewart Toland A; Scharschmidt TJ; Mayerson JL; Kraybill WG; Guttridge DC; Iwenofu OH
    Mod Pathol; 2013 Feb; 26(2):282-8. PubMed ID: 22936067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues.
    Hisaoka M; Tsuji S; Morimitsu Y; Hashimoto H; Shimajiri S; Komiya S; Ushijima M
    Diagn Mol Pathol; 1998 Apr; 7(2):96-101. PubMed ID: 9785008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
    Pollack SM; Jungbluth AA; Hoch BL; Farrar EA; Bleakley M; Schneider DJ; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
    Cancer; 2012 Sep; 118(18):4564-70. PubMed ID: 22359263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.
    Shurell E; Vergara-Lluri ME; Li Y; Crompton JG; Singh A; Bernthal N; Wu H; Eilber FC; Dry SM
    Oncotarget; 2016 Nov; 7(45):72860-72867. PubMed ID: 27655679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of p16 in lipoblastomas.
    Cappellesso R; d'Amore ES; Dall'Igna P; Guzzardo V; Vassarotto E; Rugge M; Alaggio R
    Hum Pathol; 2016 Jan; 47(1):64-9. PubMed ID: 26514741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.
    Iura K; Kohashi K; Hotokebuchi Y; Ishii T; Maekawa A; Yamada Y; Yamamoto H; Iwamoto Y; Oda Y
    J Pathol Clin Res; 2015 Jul; 1(3):144-59. PubMed ID: 27499900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of FUS-CHOP fusion gene in paraffin-embedded tissues and its clinicopathologic significance for myxoid/round cell liposarcomas].
    Xiang H; Wang J; Sun MH; Lu L; Shui RH; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2005 Jan; 34(1):28-32. PubMed ID: 15796878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DDIT3 gene break-apart as a molecular marker for diagnosis of myxoid liposarcoma--assay validation and clinical experience.
    Narendra S; Valente A; Tull J; Zhang S
    Diagn Mol Pathol; 2011 Dec; 20(4):218-24. PubMed ID: 22089349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
    Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
    Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benign recurring lipoblastoma in an adult versus well differentiated subcutaneous myxoid liposarcoma: clinicopathologic, immunohistochemical and molecular analysis of a unique case.
    Silverman JS; Hamilton J; Tamsen A
    Pathol Res Pract; 1999; 195(11):787-92; discussion 793. PubMed ID: 10605700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retroperitoneal liposarcoma with combined well-differentiated and myxoid malignant fibrous histiocytoma-like myxoid areas.
    Hisaoka M; Morimitsu Y; Hashimoto H; Ishida T; Mukai H; Satoh H; Motoi T; Machinami R
    Am J Surg Pathol; 1999 Dec; 23(12):1480-92. PubMed ID: 10584701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
    Lai JP; Robbins PF; Raffeld M; Aung PP; Tsokos M; Rosenberg SA; Miettinen MM; Lee CC
    Mod Pathol; 2012 Jun; 25(6):854-8. PubMed ID: 22388761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed-type liposarcoma: clinicopathological, immunohistochemical, and molecular analysis of a case arising in deep soft tissues of the lower extremity.
    Mentzel T; Palmedo G; Hantschke M; Woziwodzki J; Beck C
    Virchows Arch; 2008 Aug; 453(2):197-201. PubMed ID: 18551309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NY-ESO-1 as a diagnostic and prognostic marker for myxoid liposarcoma.
    Jo U; Roh J; Song MJ; Cho KJ; Kim W; Song JS
    Am J Transl Res; 2022; 14(2):1268-1278. PubMed ID: 35273728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DDIT3 Immunohistochemistry Is a Useful Tool for the Diagnosis of Myxoid Liposarcoma.
    Scapa JV; Cloutier JM; Raghavan SS; Peters-Schulze G; Varma S; Charville GW
    Am J Surg Pathol; 2021 Feb; 45(2):230-239. PubMed ID: 32815829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoblastoma-like Tumor of the Vulva, an Important Benign Mimic of Myxoid Liposarcoma.
    Creytens D
    Int J Gynecol Pathol; 2019 Mar; 38(2):204. PubMed ID: 29300200
    [No Abstract]   [Full Text] [Related]  

  • 19. New molecular insights into the pathogenesis of lipoblastomas: clinicopathologic, immunohistochemical, and molecular analysis in pediatric cases.
    Lopez-Nunez O; Alaggio R; Ranganathan S; Schmitt L; John I; Church AJ; Picarsic J
    Hum Pathol; 2020 Oct; 104():30-41. PubMed ID: 32692992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of fluorescence in situ hybridization to detect MDM2 amplification in liposarcomas and their morphological mimics.
    Kimura H; Dobashi Y; Nojima T; Nakamura H; Yamamoto N; Tsuchiya H; Ikeda H; Sawada-Kitamura S; Oyama T; Ooi A
    Int J Clin Exp Pathol; 2013; 6(7):1306-16. PubMed ID: 23826411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.